Supplements containing chromium in its trivalent oxidation state [Cr(III)] are used by diabetic patients to improve their glucose and insulin levels and omega-3 fatty acids are also beneficial for people with insulin resistance or diabetes. It seemed very useful to combine chromium(III) and omega-3 functional entities into single molecules. Here we synthesized and characterized a chromium cis-4,7,10,13,16,19-docosahexaenoic acid (DHA) complex, one of the two main components of the heterogeneous chromium(III) fish oil omega-3 concentrate products. Ethyl cis-4,7,10,13,16,19-docosahexaenoate was hydrolyzed with sodium hydroxide, and the generated salt was reacted in situ with chromium(III) chloride hexahydrate and converted into an oxo-centred trinuclear chromium(III) complex. A study of the DHA–chromium(III) complex by liquid chromatography/tandem mass spectrometry/(LC/MS/MS) is reported in this work. The data suggest a triaqua-μ3-oxohexakis-μ-docosahexaenoatotrichromium(1+), [Cr3O(C22H31O2)6(H2O)3]+, core structure.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.